Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Sells $41,444.52 in Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the sale, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Enanta Pharmaceuticals Stock Down 10.1 %

ENTA opened at $6.29 on Friday. The business has a 50 day moving average price of $10.33 and a two-hundred day moving average price of $11.96. Enanta Pharmaceuticals, Inc. has a 52 week low of $6.25 and a 52 week high of $17.80. The company has a market cap of $133.31 million, a PE ratio of -1.15 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company had revenue of $14.60 million for the quarter, compared to analysts’ expectations of $17.99 million. During the same quarter last year, the company earned ($1.33) EPS. Enanta Pharmaceuticals’s revenue for the quarter was down 22.8% compared to the same quarter last year. As a group, sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -4.81 EPS for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new position in shares of Enanta Pharmaceuticals during the second quarter worth about $35,000. US Bancorp DE boosted its holdings in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares in the last quarter. Quest Partners LLC increased its position in Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 9,692 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $122,000. Finally, Valence8 US LP acquired a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $207,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analyst Upgrades and Downgrades

ENTA has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, Robert W. Baird reduced their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.50.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.